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3Frequent abbreviations used in the thesis
BMI: body mass index
BF: body fat
MS: metabolic syndrome
SNP: single nucleotide polymorphisms
UCP2: uncoupling protein 2
GIIS: glucose induced insulin secretion
LCPUFA: long chain polyunsaturated fatty acid
n-6 LCPUFAs
linoleic acid (C18:2n-6, LA)
gamma-linolenic acid (C18:3n-6, GLA)
eicosadienoic acid (C20:2n-6)
dihomo-gamma-linolenic acid (C20:3n-6, DHGLA)
arachidonic acid (C20:4n-6, AA)
n-3 LCPUFAs
alpha-linolenic acid (C18:3n-3, ALA)
eicosapentaenoic acid (C20:5n-3, EPA)
docosapentaenoic acid (C22:5n-3)
docosahexaenoic acid (C22:6n-3, DHA)
4Introduction
Epidemiology of obesity
Obesity has become an epidemic in many parts of the world, according to numerous
studies conducted in adults and in the much limited data collected from young people
(1-3). From the 1970 to the end of the 1990s, the prevalence of overweight or obesity
in school-age children doubled or tripled in several large countries (4). In Hungary,
the prevalence of obesity increased from 12% to 16% between 1980’ and 1990’s
among schoolchildren (5). Although the increasing trend seems to be uniform in all
countries, North America, Europe and parts of the Western Pacific have the highest
prevalence of overweight among children (approximately 20-30%) (4).
By 2010, about one in every ten children in the European region is predicted to be
obese (4).
Definition of obesity
In recent years, body mass index (BMI) has been increasingly accepted as a valid
indirect measure of adipose tissue in both children and adolescents for survey
purposes (3). Currently a group of researchers developed an internationally acceptable
definition of child overweight and obesity, specifying the measurement, the reference
population, and the age and sex specific cut offs (6). In this method the percentile
levels corresponding to a BMI of 25 kg/m2 (overweight) and 30 kg/m2 (obese) at age
18 were identified and projected backwards into childhood using a large (n=97 876)
sample of youth from 6 countries (Britain, US, Holland, Singapore, Hong Kong,
Brazil).
Etiology of obesity
Obesity results from the interaction of environmental factors (inappropriate eating
behaviours and/or reduction in physical activity) and hereditary factors. This has
been shown by numerous epidemiological studies carried out in large and different
populations (7). Obesity has a very heterogeneous phenotypic expression and the
molecular mechanisms involved in its development are more than diverse.
5a.) Role of genetic factors in the etiology of obesity
According to several studies, 30 to 80% of weight variation might be determined by
genetic factors. Today, the contribution of genetic factors to obesity can be
summarized as below:
• Monogenic obesity: single mutations contribute to the development of obesity.
These forms of obesity are rare, very severe and generally start in childhood (8). To
date, nearly 200 cases of human obesity have been associated with a single gene
mutation (9;10). These cases, which obey Mendelian genetics, are characterized by
extremely severe phenotypes that present themselves in childhood and are often
associated with additional behavioural, developmental, and endocrine disorders (11).
• Syndromic obesity:  There  are  between  20  and  30  Mendelian  disorders  in  which
patients are clinically obese, yet are additionally distinguished by mental retardation,
dysmorphic features, and organ-specific developmental abnormalities (10;11). Such
cases are referred to as syndromic obesity. These syndromes arise from discrete
genetic defects or chromosomal abnormalities, and can be either autosomal or X-
linked disorders. The most common disorders known are Prader-Willi syndrome
(PWS), Bardet-Biedl syndrome (BBS), and Alström syndrome.
• Polygenic obesity: several genetic variants interact with an ‘at-risk’ environment in
common obesities. Here each susceptibility gene, taken individually, would only
have a slight effect on weight. The cumulative contribution of these genes would
become significant when there is an interaction with environmental factors
predisposing to their phenotypic expression (overeating, reduction in physical
activity, hormonal changes, and socio-economic factors).
There  are  two  main  approaches  to  identify  DNA-based  markers  associated  with
quantitative traits.
The genome-wide association study is a hypothesis-generating approach that
examines the whole genome to identify the approximate location of new genes for a
disease or trait of interest. Although this approach has proven to be successful for
mendelian disorders and for rare diseases with large genetic effects, its success in
6common  diseases  and  continuous  traits  such  as  obesity  and  BMI  has  been  limited
(12).
In the candidate gene approach genes that are thought to be involved in the
pathogenesis of different traits, based on data derived from animal models, cellular
systems, are identified. Genetic variants at these loci are then tested for association at
the population level.
The number of genetic association studies has grown exponentially over the past 15
years, which was paralleled by a vast increase in the number of candidate genes.
The CD36 gene is one of the promising candidate gene for obesity. CD36 is an 88
kDa  membrane  protein  expressed  at  the  surface  of  a  wide  variety  of  cell  types
including adipocytes, skeletal muscle cells, and monocytes/macrophages (13). It
belongs  to  the  class  of  B  scavenger  receptor  and  shows  high  affinity  toward  lipid-
based ligands such as modified low density lipoprotein and long chain
polyunsaturated fatty acids (LCPUFA) and apoptic cell membranes (13;14).
Gene invalidation and overexpression experiments indicate that CD36 plays a role in
energy metabolism, fat storage and adipocyte differentiation in mice (15;16).
Muscle-specific CD36 overexpression enhances fatty acid oxidation, decreases
plasma fatty acid (FFA), glucose and insulin levels and lowers body weight (15). In
contrast, CD36 invalidation is associated with high plasma FFA and triglycerides,
low fasting glucose levels and less weight gain on a high fat diet (17). In humans,
CD36 is also related to metabolic disorders. Firstly, CD36 deficiency (type 1) is
associated with features of metabolic syndrome (18;19). Secondly, CD36 expression
in adipocytes is positively correlated to body fat (20) and its expression is reduced
after a period of weight loss (21). Finally, several single nucleotide polymorphisms
(SNPs) in CD36 gene  have  been  associated  with  metabolic  disorders  related  to
excess fat depots (22-26), and a (TG)-repeat in intron 3 has been linked to elevated
BMI in Korean patients with coronary heart disease (CHD) (27).
These studies have assessed the association between CD36 SNPs and metabolic
disorders in adults (22;24;26). However, whether CD36 SNPs influence body fat  in
adolescents has not been reported in population studies. Genetic association studies
7in young people are important in that the influence of behavioural and exogenous
factors are less marked than in adults, leaving a larger share to the SNPs to affect the
phenotype. Therefore, the aim of the present study was to assess the relationship
between CD36 genetic variability and obesity and body fat accumulation in
adolescents.
An other well known and promising candidate gene for obesity is the uncoupling
protein 2 (UCP2) gene. The human UCP2 gene is mapped to chromosome 11q13, it
contains 8 exons and spans 8 kb (Figure 1).
Figure 1. The human UCP2 gene.
UCP2 gene is widely expressed in human tissues, including white adipose tissue,
endocrine pancreas, skeletal muscle and liver (28). The effect of UCP2 on obesity
can be due to its suspected function in energy metabolism. UCP2 might enhance the
proton leak, induce respiratory uncoupling, thereby releasing the energy stored
within the proton motive force as heat, and resulting in a decrease in ATP synthesis
(29). Furthermore, it has been shown to effect carbohydrate and lipid metabolism. In
pancreatic β-cells, increased expression or activity of UCP2 may contribute to
impairing insulin secretion by reducing the ATP-ADP ratio. The mechanism(s) by
which UCPs may enhance lipid catabolism is still unknown, but could rely on their
ability to transport fatty acid anions outside of the mitochondrial matrix. (30).
The variant A allele of the common -866G/A polymorphism in the promoter
region of the human UCP2 gene enhances its transcriptional activity. The
enhancement results in increased UCP2 mRNA levels in human fat cells;
consequently, this polymorphism is associated with a reduced risk of obesity but an
increased risk of type 2 diabetes (31;32). Recently, an association between obesity,
disorders of lipid and carbohydrate metabolism and the G-allele of the -866G/A
polymorphism in the promoter region of UCP2 gene was reported (33).
8In the present study, we investigated the fatty acid composition of plasma lipids
and the association of n-6 LCPUFAs to glucose induced insulin secretion (GIIS)
evaluated by standard oral glucose tolerance test (OGTT) in obese children stratified
according to the -866 G/A polymorphism of UCP2.
b.) Role of long chain polyunsaturated fatty acids in the etiology of obesity
Several environmental factors affect the obesity phenomenon significantly. Evidence
has accumulated showing that early nutrition programs later obesity risk. The
mechanisms involved are poorly understood, beside the role of several nutrients,
LCPUFAs may also play a significant role.
LCPUFAs are fatty acids with a minimum chain length of 18 carbons containing at
least 2 double bonds. LCPUFAs are classified into 1 of 2 families: n-3 and n-6
(Figure 2).
Figure 2. The metabolism of n-3 and n-6 fatty acids.
9The n-3 and n-6 nomenclature refers to the location of the first unsaturated carbon
from the methyl (‘n’) terminus of the fatty acid. The first double bond is located at
carbon 3 for n-3 fatty acids and at carbon 6 for n-6 fatty acids. Alpha-linolenic acid
(ALA, C18:3n-3) and linoleic acid (LA, C18:2n-6) are the parent compounds for the
n-3 and n-6 series of LCPUFAs, respectively. Because humans lack the ability to
insert a double bond prior to carbon 9 in the fatty acid chain, ALA and LA cannot be
synthesized endogenously and are therefore dietary essential fatty acids.
The role of LCPUFA in obesity development is supported by several facts. First,
both in rodents and humans, LCPUFA (especially arachidonic acid [AA, C20:4n-6])
enhances the formation of adipocytes. When compared to control adipogenic
conditions,  a  brief  exposure  of  preadipocytes  to  LCPUFAs  appears  sufficient  to
trigger in vitro both hyperplasia and hypertrophy (34). Secondly, LCPUFA is known
to influence gene expression of lipolytic and glycolytic enzymes (35) and proteins
regulating energy metabolism and thermogenesis (for example PPARγ and UCP2),
leading to changes in metabolism, growth, and cell differentiation. Third, a recent
study showed that overweight and symptoms of metabolic syndrome can be
programmed in the adult animal by modulating essential LCPUFA in the perinatal
period (36). Fourth, human studies also provide evidence that obesity per se is
associated with a disturbed n-6/n-3 LCPUFA balance in the maternal diet during
pregnancy, lactation, and early childhood (37). Finally, different LCPUFA
composition of obese patients compared to normal weight controls were reported in
studies (38;39). Previously we found significantly higher percentage contributions of
the n-6 long-chain polyunsaturated fatty acids, gamma-linolenic acid (GLA, C18:3n-
6), dihomo-gamma-linolenic acid (DHGLA, C20:3n-6), and AA, to the fatty acid
composition of plasma lipid classes in obese children than in nonobese controls (38).
Beside the potential role in obesity development, LCPUFAs have several other
important functions as well. The availability of LCPUFAs and especially the supply
of docosahexaenoic acid (DHA, C22:6n-3) appears to modify the development of
visual and cognitive functions during early life (40-44). The LCPUFA content of the
diet influences membrane structure and function, and also effects the production of
second messengers, such as eicosanoids that influence many cell-associated
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functions (45). During gestation and infancy, the supply of preformed LCPUFA can
influence neural functions (45).
Essential fatty acids can not be synthesised by humans and must be supplied
through placental transport to the fetus and with human milk or milk substitute
formulae to the infant. Human milk supplies not only the essential fatty acids linoleic
and alpha-linolenic acids, but also their LCPUFA metabolites (40;46). It provides
considerable amounts of LCPUFAs, and is considered to provide optimal form of
nutrition for young infants (46-49). During gestation, major amounts of DHA and
other  LCPUFAs  are  transferred  to  the  developing  fetus  for  optimal  growth  and
development by an active and selective transport (50;51). Tissue values of AA and
DHA increases steadily with increasing gestational age (52); LCPUFAs accumulate
in the fetus, especially during the last trimester of pregnancy (40;47;53).
Lipid content and fatty acid composition of human milk is reportedly influenced
by a variety of variables such as genetic background of the lactating woman,
maternal nutritional status, maternal dietary intakes immediately before and during
gestation, the number of previously breastfed infants and the stage of lactation
(40;47;52). It has also been debated whether fatty acid composition of human milk
differs after preterm as compared to full-term delivery (54-58). In our previous study
percentage contributions of arachidonic and docosahexaenoic acids as well as those
of the intermediary metabolites of essential fatty acid metabolism were all
significantly higher in early human milk samples of mothers giving birth to very low
birth weight preterm as compared with full-term infants (58).
Preterm infants represent a small (about 5% to 10%, depending on several
genetic and socioeconomical factors), but highly vulnerable subgroup of infants.
Optimal nutrition of preterm infants, including the prevention of obesity, is of
obvious importance from the point of view of the health of the community. However,
solid information of the composition of human milk of mothers of preterm infants is
a  prerequiste  of  the  optimisation  of  the  composition  of  formulae  to  be  used  in  the
nutrition of premature babies. In this study we systematically reviewed the published
information on fatty acid composition of human milk in mothers of preterm as
compared to those of full-term infants.
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Metabolic consequences of obesity
As the prevalence of childhood obesity increases, its health implications are
becoming more evident. Obesity is associated with significant health problems in the
pediatric age group and is an important early risk factor for much of adult morbidity
and mortality. Many of the metabolic and cardiovascular complications of obesity
are already present during childhood. In fact, there are few organ systems that
obesity does not affect (59).
According to the latest estimates of Lobstein et al. over 27 000 obese children in the
European Union have type 2 diabetes (most of it unrecognised and hence untreated),
and over 400 000 have impared glucose tolerance (60).
Over a million obese children are likely to have a range of cardiovascular disease
indicators, with an estimated 1.1 million suffering hypertension (61). Nawrot and
colleagues (62) report that systolic blood pressure increases by 0.8 mmHg per 1
kg/m2 increase in BMI in 15 to 19 year old males and by and 1.2 mmHg per 1 kg/m2
increase in BMI in 15 to 19 year old females. In the Bogalusa Heart Study youth with
BMI values >75th percentile were 8.5 times more likely to become hypertensive as
adults than were their lean counterparts (63).
Obese children and adolescents have consistently been observed to have a more
unfavourable lipid and lipoprotein profile than children and adolescents with a
normal body weight (61). 52% of obese children 8 to 12 years old were found to
have elevated total cholesterol concentrations compared with a prevalence of 16% in
non-obese children (64). There is increasing evidence that atherosclerosis begins in
childhood (65;66); however, the rate of progression is directly related to plasma
lipoprotein concentrations (67). In the Bogalusa Heart Study, autopsy studies of
children showed a clear relationship between the number and severity of risk factors,
principally obesity, with atherosclerosis in both the aorta and coronary arteries (68).
Overweight and obesity in youth plays a central role in the metabolic syndrome
(MS) - defined as a clustering of insulin resistance/hyperinsulinemia, dyslipidemia
and hypertension. A recent publication estimated the prevalence of MS in Europe on
the basis of data obtained from a literature search and extrapolated them to the 25
member states (60). Most of the studies used for the calculation of weighted average
prevalence were performed on USA children (n=6) and only one was European (69).
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Concerning the definition of MS in children and adolescents no consensus has
been reached yet, although the clustering of metabolic risk factors was described in
children long before the term “metabolic syndrome” emerged (70-72). The adult
definitions of MS (World Health Organization [WHO] (73), European Group for the
Study of Insulin Resistance [EGIR] (74), National Cholesterol Education Program
Adult Treatment Panel III [NCEP] (75), International Diabetes Federation [IDF]
(76),  American  Heart  Association  (77))  varying  in  terms  of  the  criteria  and  cut  off
points and do not apply to children because of the age- and sex- dependent changes
in  several  of  the  components  of  the  MS.  In  the  majority  of  the  studies  on  MS
performed in children and adolescents, the authors adapted the criteria from the adult
definitions with widely varying risk factor cut-offs. The main differences concerning
the definitions are the techniques used to estimate adiposity BMI or waist
circumference) and the variables for evaluating glucose metabolism (fasting glucose,
fasting insulin, hyperinsulinemia/insulin resistance, IGT or known type 2 diabetes).
Recently,  the  IDF proposed  its  own pediatric  definition  of  MS (78),  which  follows
the adult IDF definition, and the cut-off points are identical to those used for adults,
despite the more favorable distribution of lipid profiles and blood pressure normally
found  in  childhood  (79).  The  aim  of  the  present  study  was  to  review  the  data
concerning the prevalence of metabolic syndrome in European children and
adolescents, and to determine and compare the prevalence of MS among overweight
and obese children and adolescents in five European countries using four MS
definitions.
The presence of multiple metabolic disorders persists from childhood into
adulthood 25%–60% of the time (70;80). The alarming increases in obesity in
developing  countries  has  led  the  World  Health  Organization  to  estimate  that
cardiovascular disease CVD will rise from number 5 to number 1, the leading killer
in the entire world after another decade (2;81).
For  all  these  reasons,  CVD  is  and  will  remain  the  leading  killer  in  the  most
developed countries. Thus, the long-term consequences of childhood obesity could
cause our current generation of children to become the first in the history to have a
decreased life expectancy than their parents (82;83).
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Aims of the study
1. Association among single nucleotide polymorphisms at CD36 locus and
obesity in European adolescents
a.) To explore the relationship between polymorphisms in the CD36 gene and obesity
in a case-control study of adolescents.
b.) To validate our findings on anthropometric markers of obesity in an independent
cross sectional study of European adolescents.
2. Association of n-6 long-chain polyunsaturated fatty acids to -866G/A
genotypes of the human uncoupling protein 2 gene in obese children
a.) To examine the effect of −866 G/A polymorphism of UCP2 on the fatty acid
composition of plasma lipids in obese children.
b.) To investigate the association of n-6 long-chain polyunsaturated fatty acids
(LCPUFAs) with glucose-induced insulin secretion (GIIS) in obese children
stratified according to the −866 G/A polymorphism of UCP2.
3. Systematic review of fatty acid composition of human milk from mothers of
preterm compared to full-term infants
To systematically review the published information on fatty acid composition of
human milk in mothers of preterm as compared to those of full-term infants.
4. Prevalence of metabolic syndrome in European obese children
a.) To review the data concerning the prevalence of metabolic syndrome in European
children and adolescents.
b.) To determine and compare the prevalence of MS among overweight and obese
children and adolescents in five European countries using four MS definitions.
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1. Association among single nucleotide polymorphisms at CD36
locus and obesity in European adolescents European adolescents
Patients and methods
The Pécs Case-control study of adolescent obesity. The study population consist of
307  obese  adolescents  referred  to  the  outpatient  clinic  of  the  Department  of
Pediatrics  University  of  Pécs  (Pécs,  Hungary)  for  obesity  and  339 healthy normal
weight adolescents recruited via general schools of Pécs aged between 14-17 years.
Obesity was defined as a BMI over the value given by Cole et al. (84), corresponding
to 30 kg/m2 at the age of 18 years. None of the subjects had chronic diseases, was
taking  drugs  or  was  dieting.  Blood  samples  for DNA extraction was collected in
EDTA K3 tubes. Genomic DNA was extracted from peripheral blood leukocytes
according to standard procedures.
HELENA cross-sectional study (HELENA-CSS) (validation setting). Recruitment
and phenotyping of the participating adolescents in the HELENA study ("Healthy
Lifestyle in Europe by Nutrition in Adolescence", www.helenastudy.com) have been
described previously (85). Briefly, a total of 3865 adolescents were recruited
between 2006 and 2007. Data were collected in 10 centres from 9 European
countries (86). Subjects were randomly selected according to a proportional cluster
sampling methodology taking into account geographical repartition in each city,
private/public school ratio, and number of classes by school. One third of the classes
were randomly selected for blood collection, resulting in a total of 1155 blood
samples for the subsequent clinical biochemistry assays and genetic analyses.
Anthropometry. Skinfold thicknessess were measured at 6 sites: bicipital, tricipital,
sub-scapular, suprailiac, thigh and calf using a Holtain Caliper. Reliability of
skinfolds thickness measurements were adequate for epidemiological surveys (87).
The percentage of body fat (BF%) was estimated from skinfold measurements
according to the equations of Parizkova et al (88). The BMI was calculated.
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Blood analysis. Blood for DNA extraction was collected in EDTA K3 tubes, stored
at the Analytical Laboratory at the University of Bonn and then sent to the Genomic
Analysis Laboratory at the Institut Pasteur de Lille (IPL) in France (89). DNA was
extracted from white blood cells with the Puregene kit (QIAGEN, Courtaboeuf,
France) and stored at -20°C.
In both the Pécs Case-control study and the HELENA-CSS data were collected on a
detailed case report form according to standardised procedures. In each centre,
trained nurses and physicians carried out complete physical examinations including
weight, height and blood pressure.
For both studies, the protocol was approved by the ethics committee of each
recruiting centre (90). A written, informed consent was obtained from each
adolescent and both of his/her parents or legal representatives. Participation in the
studies was voluntary.
Gene selection and genotyping. With the criterion used in our SNP selection
procedure (a minor allele frequency (MAF) above 0.1 and tag SNPs with an r2 value
above 0.8), the HapMap database (2007 release) describes 5 haplotype blocks and 2
independent SNPs that span the whole gene. In the present study, we selected 1 SNP
from each of the five haplotype blocks (block 1: rs1527479, block 2: rs3211816,
block 3: rs3211867, block 4: rs3211883 and block 5: rs3211931) and the two
independent SNPs (rs3211908 and rs1527483). We also selected 3 other SNPs
(rs1984112, rs1761667 and rs1049673) from the literature (24) in order to cover the
whole range of gene variability (Figure 3). Altogether, subjects were genotyped on
an Illumina system, 1 SNP (rs1761667) using the VeraCode technology and the 9
other SNPs using GoldenGate technology.
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Figure 3. The CD36 gene and the selected single nucleotide polymorphisms.
Statistical methods. Statistical analyses were performed with SAS software (SAS
Institute Inc., Cary, NC, USA). Departure from the Hardy–Weinberg equilibrium
within the study groups was tested using a χ2 test. Inter-locus linkage disequilibrium
was tested using a log-likelihood-ratio test (91) and expressed in terms of a
normalised difference D’=D/Dmax or D/Dmin (92). Allele frequencies were
estimated  by  gene-counting.  In  the  Pecs  case-control  study,  multivariate  logistic
regression was used to calculate the odds ratio of obesity for different allele
exposures, using different genetic models. Adjustment variables were age and
gender. The General Linear Model (GLM) was used to compare mean values of
anthropometric markers among genotypes in the cross sectional study. Adjustment
variables were age, gender and centre. Dominant and recessive models were tested.
For the case-control study the statistical significance threshold was set to p ≤ 0.007
after Bonferroni correction and to p ≤ 0.05 for the HELENA-CSS. Haplotype
analyses were based on a maximum likelihood model (93) linked to the SEM
algorithm (94) and performed using Thesias software developed by INSERM unit
U525, Paris, France (http://ecgene.net/genecanvas).
Results
Table 1 shows the clinical characteristics of the subjects from the case-control and
the cross-sectional studies. The mean age years (SD) of the obese and normal weight
adolescents of the case-control study was 15.0 (1.1) and 14.6 (1.1) respectively, and
14.8 (1.4) years for the adolescents of the cross-sectional study. There were more
girls among the normal weight controls and in the cross-sectional study than in the
group of obese adolescents. As expected obese adolescents had significantly higher
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BMI and BF% compared to normal weight adolescents of the case-control study (all
p<0.001).
Table 1. Characteristics of the subjects
Normal weight Obese
n 339 307 1155
Boys/girls 164/175 165/142 552/603
Age (years) 15.0 (1.1) 14.6 (1.1) 14.8 (1.4)
Weight (kg) 56.4 (8.9) 91.4 (18.6) 58.3 (13.0)
Height (cm) 168.4 (8.7) 166.8 (8.8) 165.0 (9.6)
BMI (kg/m2) 20.1 (2.5) 32.7 (5.5) 21.3 (3.7)
BF (%) 25.1 (6.4) 39.4 (6.0) 26.5 (6.9)
Systolic BP (mmHg) 118.6 (13.5) 127.6 (11.0) 118.2 (13.8)
Diastolic BP (mmHg) 66.6 (8.6) 72.4 (8.4) 67.3 (9.8)
Obesity case-control study HELENA cross-
sectional study
BMI: body mass index, BF: body fat, BP: blood pressure
DNA samples were genotyped for the 10 selected CD36 SNPs  (Figure  3). The
genotyping success rate varied between 97.1 and 100%. In each study, all the
observed SNP frequencies obeyed the Hardy–Weinberg equilibrium. The linkage
disequilibrium pattern for the SNPs was assessed in the HELENA-CSS using both
the D’ and r2 values (Figure 4). The 3 SNPs selected from literature data (rs1984112,
rs1761667 and rs1049673) were in strong linkage disequilibrium with three
haplotype blocks described by the HapMap database (rs1761667 with rs1527479
(block 1) [D’ = 0.98, r2 = 0.93], rs1984112 with rs3211816 (block 2) [D’ = 0.97, r2 =
0.89], and rs1049673 with rs3211931 (block 5) [D’ = 1, r2 = 0.98]). Thus, further
analyses were performed with the 7 following SNPs: rs1527479, rs3211816,
rs3211867, rs3211883, rs3211908, rs3211931 and rs1527483.
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rs1984112
66 rs1761667
63 93 rs1527479
89 61 65 rs3211816
4 7 8 4 rs3211867
5 10 11 5 67 rs3211883
3 5 4 2 61 43 rs3211908
27 40 41 28 1 3 5 rs3211931
2 3 3 1 41 29 63 8 rs1527483
28 40 41 28 1 2 5 98 8 rs1049673
D' > 90
90> D' >70
70> D' >60
60> D' >40
Figure 4. The linkage disequilibrium pattern (D’ and r2) across the investigated
SNPs of the CD36 gene. Color is D’, values are r2.
Table 2 shows the genotype distribution of the 7 SNPs in obese and normal weight
subjects, the age- and gender- adjusted odds ratio (OR) and the 95% confidence
interval (95%CI) for obesity from the case-control study. In a dominant model, 4
SNPs were associated with a higher risk of obesity (rs3211867: OR [95%CI]= 1.96
[1.26-3.04], p=0.003; rs3211883: OR=1.73 [1.16-2.59], p=0.007; rs3211908:
OR=2.42 [1.47-4.01], p=0.0005 and rs1527483: OR=1.95 [1.25-3.05], p=0.003).
After Bonferroni correction (significance: p≤0.007), the rs3211867, rs3211883,
rs3211908 and rs1527483 SNPs were still significantly associated with a greater risk
of obesity.
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Table 2. Genotype distribution of the investigated SNPs in obese and control subjects of the Pécs case-control study
11 12 22 11 12 22
rs1527479 98 (0.29) 174 (0.52) 66 (0.19) 64 (0.21) 155 (0.51) 86 (0.28) 0,01 1,42 [1.06-2.10] 0,09
rs3211816 134 (0.40) 162 (0.48) 40 (0.12) 111 (0.36) 152 (0.50) 43 (0.14) 0,55 1,13 [0.82-1.57] 0,44
rs3211867 299 (0.882) 40 (0.118) 0 244 (0.797) 60 (0.196) 2 (0.007) 0,004 1,96 [1.26-3.04] 0,003
rs3211883 284 (0.840) 53 (0.157) 1 (0.003) 233 (0.764) 68 (0.223) 4 (0.013) 0,03 1,73 [1.16-2.59] 0,007
rs3211908 311 (0.917) 28 (0.083) 0 255 (0.831) 49 (0.160) 3 (0.009) 0,0009 2,42 [1.47-4.01] 0,0005
rs3211931 108 (0.32) 163 (0.48) 66 (0.20) 84 (0.27) 149 (0.49) 74 (0.24) 0,26 1,26 [0.89-1.78] 0,19
rs1527483 299 (0.885) 39 (0.115) 0 248 (0.808) 55 (0.179) 4 (0.013) 0,004 1,95 [1.25-3.05] 0,003
[95% CI] p**
Normal weight Obese
p* OR
Data are n (freq). Frequent allele :1 ; Minor allele: 2. p* value is for chisquare test. ORs and p** values are for dominant model. p values are
adjusted for age and gender
20
Table 3 shows the BF% and BMI as a function of the CD36 genotypes in the cross-
sectional study. Multivariate analyses (adjusted for age, gender and centre) revealed
that  the  mean  BMI  and  BF%  were  significantly  higher  in  carriers  of  at  least  one
minor allele with rs3211867 (BMI: p=0.03, BF%: p=0.02), rs3211883 (BMI: p=0.03,
BF%: p=0.05), rs3211908 (BMI: p=0.04, BF%: p=0.02) and rs1527483 (BMI:
p=0.05, BF%: p=0.04) compared with individuals who were homozygous for the
frequent allele. These associations were not modified by further adjustment for
pubertal status (data not shown).
Haplotype analyses using the 7 SNPs (order: rs1527479, rs3211816, rs3211867,
rs3211883, rs3211908, rs3211931 and rs1527483) were performed to assess the
relationship with obesity in the case-control study and the association with BMI and
BF% in the HELENA-CSS. Nine haplotypes had an estimated frequency of over 1%
(Table 4/a, 4/b). Compared with the most common haplotype (GGCTGGG;
estimated frequency: 0.44), 1 haplotype: AGAAAAA (estimated frequency: 0.05,
minor  alleles  underlined)  was  significantly  associated  with  a  higher  risk  of  obesity
(OR: 2.28 for obesity; p=0.0008). This haplotype was also associated with a higher
BF% (p=0.03) and BMI (p=0.04) in the cross-sectional study.
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Table 3. Genotype  distribution  and  mean  values  of  body  mass  index
and body fat percentage according to the SNPs in the HELENA-CSS
11 12 22 p dominant
rs1527479 GG (n=326) GA (n=557) AA (n=261)
BMI 21.0 (3.5) 21.3 (3.9) 21.6 (3.7) 0,30
BF% 26.2 (6.8) 26.4 (7.1) 26.9 (6.6) 0,28
rs3211816 GG (n=449) GA (n=503) AA (n=161)
BMI 21.2 (3.6) 21.4 (3.8) 21.4 (3.7) 0,72
BF% 26.5 (6.6) 26.3 (7.2) 26.8 (6.6) 0,38
rs3211867 CC (n=999)
BMI 21.2 (3.7) 0,03
BF% 26.4 (6.9) 0,02
rs3211883 TT (n=945)
BMI 21.2 (3.7) 0,03
BF% 26.4 (6.9) 0,05
rs3211908 GG (n=1041)
BMI 21.3 (3.7) 0,04
BF% 26.4 (6.9) 0,02
rs3211931 GG (n=339) GA (n=575) AA (n=230)
BMI 21.0 (3.4) 21.4 (3.7) 21.6 (4.2) 0,19
BF% 26.2 (6.7) 26.5 (7.2) 26.9 (6.9) 0,58
rs1527483 GG (n=1002)
BMI 21.3 (3.7) 0,05
BF% 26.4 (6.9) 0,04
21.8 (3.8)
21.7 (3.6)
21.7 (3.8)
CA (n=139) + AA (n=6)
27.3 (6.8)
TA (n=189) + AA (n=10)
26.8 (6.8)
27.1 (6.9)
21.7 (4.0)
GA (n=101) + AA (n=2)
27.4 (6.8)
GA (n=138) + AA (n=4)
Data are means (SD). Frequent allele :1 ;  Minor allele:  2.  BMI: body
mass index, BF: body fat. P values are adjusted on age, center and
gender.
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Table 4/a. Haplotype frequencies, OR and 95% CI in the case-control study
Haplotype Frequency OR 95% CI p
GGCTGGG 0,44 reference
AACTGAG 0,29 0,98 0.77-1.26 0,52
AACTGGG 0,07 1,58 1.01-2.48 0,13
GGCTGAG 0,05 0,93 0.55-1.58 0,82
AGAAAAA 0,05 2,28 1.33-3.92 0,0008
AGCAGAG 0,02 1,18 0.50-2.77 0,37
AGAAGGG 0,01 1,66 0.56-4.87 0,34
GGCTGAA 0,01 0,69 0.22-2.15 0,69
AGCTGAG 0,01 0,75 0.23-2.41 0,58
Table 4/b. Haplotype frequencies, delta values of mean BF% and delta values
of mean BMI in the HELENA-CSS
Haplotype Frequency delta BF % p delta BMI p
GGCTGGG 0,45 reference reference
AACTGAG 0,28 0,25 0,44 0,08 0,62
AACTGGG 0,07 0,22 0,70 0,12 0,69
GGCTGAG 0,06 0,38 0,54 0,22 0,49
AGAAAAA 0,04 1,5 0,03 0,76 0,04
AGCAGAG 0,02 0,08 0,92 0,02 0,93
AGAAGGG 0,02 -0,14 0,92 0,09 0,87
GGCTGAA 0,01 0,11 0,96 -0,15 0,82
AGCTGAG 0,01 1,42 0,33 0,5 0,51
Only haplotypes with a frequency above 1% are presented. Order of the SNPs
used for the analysis: rs1527479, rs3211816, rs3211867, rs3211883, rs3211908,
rs3211931, rs1527483. Minor alleles for each SNP are underlined. Delta BF
refers to the mean percentage of BF difference between the common haplotype
(GGCTGGG) and other haplotypes.
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Discussion
The results of the present study showed that rs3211908 was consistently associated
to a higher risk of obesity in the case-control study and excess adiposity in the cross-
sectional study. Further analyses identified a haplotype carrying the minor allele of
rs3211908 that was linked with obesity and a higher body fat percentage in
adolescents. These findings suggest that CD36 gene  variability  is  associated  to  the
risk of fat accumulation in adolescents.
The rs3211867, rs3211883 and rs1527483 SNPs were also related to the risk of
obesity and the BF% although the associations were weaker. The later SNPs were in
partial linkage disequilibrium with rs3211908 (0.43< r2 <0.64), suggesting that these
associations reflect a single signal. This hypothesis was further supported by the
haplotype analysis which showed that only one haplotype carrying the rs3211908
variant was associated with obesity and BF%. All other haplotypes were not
consistently linked to excess body fat suggesting that the culprit variant is the minor
allele of rs3211908. Finally, the remaining SNPs (rs1527479, rs3211816 and
rs3211931) were not linked to an excess fat deposition phenotype.
Rs3211908 is located 100 bp down-stream the donor site of exon 7, that
codes the amino acids corresponding to the interaction region with the LCPUFAs
(95). The Genomatix MatInspector software (www.genomatix.de), a functional
analysis tool, indicated that the T allele of rs3211908 abolishes a predicted
glucocorticoid receptor binding site (responsive element) which may affect CD36
gene expression. Alternatively, rs3211908 SNP could be in linkage disequilibrium
with a yet undetected functional SNP located elsewhere in the CD36 gene.
Several hypotheses might explain the link between CD36 genetic variability
and body fat depot. Firstly, CD36 is a cell membrane transporter of LCPUFA in a
wide variety of metabolically active tissues, including heart, muscle and adipocytes
(96). A defect in CD36 function could decrease the rate of fatty acids oxidation in
muscles and thus increase the availability of fatty acids for storage in adipocytes
(97;98). Secondly, cell co-culture experiments have shown that activated
macrophages secrete various factors that inhibit the formation of mature adipocytes
(99). A dysregulation of CD36 in macrophages embedded in the adipose tissue could
alter the signalling pathway that retrocontrol adipocyte expansion (99). Thirdly,
trough the provision of LCPUFA and oxidised low density lipoprotein cholesterol,
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CD36 plays a key role in the activation of peroxisome proliferator-activated receptor
gamma (PPAR-γ) (100;101), a nuclear receptor responsible of adipocyte
differentiation and adipogenesis (102). Thus an alteration of CD36 may impact
PPAR-γ mediated adipocyte differentiation (103).
This study has several strengths and limitations. The analyses were carried
out in 2 independent samples of European adolescents reducing the likelihood of
spurious findings. The study was performed in adolescents, thus providing an
advantage to discover unknown associations. One concerns is the limited number of
SNPs used to tag CD36 gene  due  to  the  selection  of  tag  SNPs  with  a  minor  allele
frequency >0.10, which does not allow the identification of rare alleles with possible
stronger influences.
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2. Association of n-6 long-chain polyunsaturated fatty acids to -
866G/A genotypes of the human uncoupling protein 2 gene in obese
children
Patients and methods
The investigations were carried out in 80 obese children (age: 13.0 [2.7] (8.1 – 17.0)
years, body mass index: 41.7 [4.4] (27.3 – 49.7) kg/m2, body fat: 39.1 [4.2] (31.6 –
56.1) %, mean [SD] (min. – max.)) referred to the Outpatient Clinic for Obesity of
the Department of Paediatrics, University of Pécs, (Pécs, Hungary) because of their
overweight. None of the subjects had any chronic disease, they did not receive any
drug treatment, and none of them were dieting. We considered children as obese if
their body weight exceeded the normal weight for height by more than 20%, and if
body fat content was higher than 25% in boys and 30% in girls.
The study was carried out in accordance with the Declaration of Helsinki II
and  with  approval  of  the  ethics  committee  of  the  University  of  Pécs.  Informed
parental consent was obtained for each child before enrolment into the study. All
participants remained anonymous throughout the survey.
Anthropometric measurements were carried out by the same investigator.
Body height and weight were measured in the survey unit with approved medical
care instruments, and body mass index was computed as weight (kilograms) divided
by squared height (meters squared). The waist and hip circumferences were
measured with the subject in the supine position. Body fat was estimated according
to Parizkova and Roth (104) from five skinfold thicknesses measured on the left side
of  the  body  three  consecutive  times  with  the  help  of  a  Holtain  caliper.  Lean  body
mass was calculated by subtracting body fat from actual body weight. Relative body
weight was calculated as the ratio between the actual body weight and the ideal body
weight for age, gender and height (105).
Blood samples were taken after an overnight fast. Plasma glucose
concentrations were determined by the glucose oxidase method. Plasma insulin
concentrations were measured with commercially available radioimmunoassay kits
(Isotope Institute of the Hungarian Academy of Sciences, Budapest, Hungary). With
this method, the cutoff value for insulin was 18.7 μU/ml (95th percentile value of 100
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healthy children). The OGTT consisted of oral administration of glucose (1.75 g/kg
body weight, maximum 75 g) followed by plasma glucose and insulin determinations
at 30, 60, 90, 120, and 180 min. The test results were evaluated according to the
recommendation of the American Diabetes Association (106). Triacylglycerol and
cholesterol were determined with an enzymatic kit (Boehringer Mannheim,
Mannheim, Germany). High-density lipoprotein cholesterol was measured by the
precipitation method of Steele et al (107).
Genomic DNA was extracted from peripheral blood leukocytes according to
standard procedures. The -866 G/A polymorphism in the promoter region of the
human  UCP2  gene  was  investigated  with  polymerase  chain  reaction  (PCR)  and
subsequent diagnostic restriction fragment length polymorphism analyses (RFLP)
with the restriction enzyme Bsh1236I which either cut (-866 G-allele) or did not cut
(-866 A-allele) the 201 basepair (bp) PCR amplicon. The primers used were: forward
primer 5’-TGACTGAACGTCTTTGGGACT-3’ and reverse-primer 5’-
GATGAGAAAAGCCGTCAGGA-3’. PCR was performed by initial denaturation at
94°C for 3 min, 36 cycles at 94°C for 30 s, 57°C for 30s, 72°C for 30s, and a final
extension at 72°C for 4 min. The samples were then run on a 3.0% agarose gel,
stained with ethidium bromide and analysed under ultraviolet light.
Venous blood samples for lipid analysis were taken from the antecubital vein
into tubes containing 2 mg/ml EDTA as anticoagulant. The plasma was removed
within 30 min and stored at –80 °C until analysis. All samples were thawed only
once.
Fatty acids were analysed by high-resolution capillary gas-liquid
chromatography using a Finnigan 9001 gas chromatograph (Finnigan/Tremetrics
Inc., Austin, TX, USA) with split injection (ratio: 1 to 25), automatic sampler
(A200SE, CTC Analytic, Switzerland) and flame-ionisation detector with a DB-23
cyanopropyl  column  of  40m  length  (J  &W  Scientific,  Folsom,  CA,  USA).  The
analytical procedure is described in detail elsewhere (108). Peak identification was
verified by comparison with authentic standards. Fatty acid results were expressed as
percentages (weight by weight) of fatty acids detected with a chain length between
12 and 24 carbon atoms.
Statistical analysis Results  were  evaluated  with  SPSS  for  Windows,  Release  11.5
(SPSS  Inc.,  Chicago,  IL,  USA).  All  data  except  fatty  acids  are  presented  as  mean
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(SD) and were evaluated by analysis of variance followed by the least significant
difference comparison test to compare mean values of subgroups. The fatty acid data
are presented as median and range from the first to the third quartile values, because
skewed distributions were found in several parameters, especially in fatty acids
present at low concentrations. Fatty acids were analysed by the Kruskal-Wallis
nonparametric analysis of variance followed by Mann-Whitney’s twosided rank test
to compare median values of subgroups. Results were regarded as statistically
significant at p<0.05. Nonparametric Spearman’s correlation analysis was performed
in order to determine the relationship between plasma fatty acids and plasma insulin
concentrations during OGTT. Because more than one correlation was calculated, we
performed Bonferroni corrections to have a more conservative estimate of the p
value.
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Results
The clinical features of the study subjects are shown in Table  5. There was no
significant difference among the groups in anthropometric indices of obesity, in the
concentrations of plasma lipid classes, or in fasting plasma glucose and insulin
concentrations (Table 5).
Table 5. Main clinical characteristics of 80 obese children stratified according
to the -866 G/A polymorphism in the promoter region of the uncoupling
protein 2 (UCP2)
-866G/G -866G/A -866A/A
(n = 34) (n = 34) (n = 12)
Sex (male:female) 22:12 16:18 5:07
Age (yr) 12.8 (2.7) 12.6 (2.9) 13.8 (2.7)
Weight (kg) 79.2 (21.7) 75.6 (23.0) 73.8 (21.4)
Height (cm) 159 (16) 157 (12) 154 (9)
BMI (kg/m2) 30.7 (4.2) 29.8 (4.9) 30.6 (6.2)
LBM (kg) 48.0 (12.4) 45.7 (13.1) 43.7 (8.6)
RBW (%) 167.7 (20.0) 164.8 (21.7) 173.2 (26.3)
BF (%) 38.9 (4.5) 39.1 (3.5) 39.3 (5.7)
Waist/hip ratio 0.85 (0.05) 0.85 (0.09) 0.86 (0.06)
HDL-cholesterol (mmol/L) 1.16 (0.35) 1.33 (0.46) 1.28 (0.50)
Total cholesterol (mmol/L) 4.19 (0.74) 4.23 (0.61) 4.42 (0.93)
Triglyceride (mmol/L) 1.39 (0.56) 1.32 (0.42) 1.78 (1.29)
Fasting plasma glucose (mmol/L) 4.3 (0.77) 4.1 (1.78) 3.96 (0.71)
Fasting plasma insulin (µU/mL) 26.86 (13.61) 24.77 (10.84) 23.08 (12.28)
UCP2 genotype:
Data  are  mean  (SD).  BMI,  body  mass  index;  LBM,  lean  body  mass;  RBW,
relative body weight; BF, body fat content; HDL-cholesterol, high-density
lipoprotein cholesterol
In plasma phospholipids (Table  6)  and  sterol  esters  (Table  7), there were no
significant differences in the values of 33 individual fatty acids including 8 saturated,
10 cis-monounsaturated, 3 trans-isomeric, 8 n-6 polyunsaturated and 4 n-3
polyunsaturated fatty acids. In contrast, values of eicosadienoic acid (C20:2n-6) were
significantly lower in plasma phospholipids in children with the -866A/A genotype
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than in the other two groups. Values of dihomo-γ-linolenic acid (DHGLA, C20:3n-6)
were significantly lower in children with the -866A/A than in those with the -866G/A
genotype in plasma phospholipids (Table 6) and were significantly lower in children
with the -866 A/A genotype than in the other two groups in plasma sterol esters
(Table 7).
In the phospholipid fraction, C20:3n-6 values in children with the -866G/G
genotype showed significant positive correlations with plasma insulin concentrations
at 60 minutes of the OGTT (Table 8). No such correlation was seen in children with
-866A/A and -866G/A genotype. In plasma sterol esters, C20:3n-6 values showed
significant positive correlation with plasma insulin concentrations at 60 minutes of
the OGTT in children with the -866G/G and -866G/A, but not in those with the -
866A/A genotype (Table 8). Significant inverse correlations were seen at 0, 30 and
60 minutes of the OGTT between C20:4n-6 and insulin values in children with the -
866A/A genotype (Table 8). No such negative correlation was seen in the other two
groups.
Figure 5 shows the correlation between insulin area under the curve during OGTT
and the values of C20:4n-6 in sterol ester lipids. Significant inverse correlation was
seen in children with the -866A/A genotype between C20:4n-6 and the insulin area
under the curve, whereas no such correlation was observed in the other groups.
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Table 6. Fatty  acid  composition  of  plasma phospholipids in 80 obese
children stratified according to genotype in the promoter of the uncoupling
protein 2 (UCP2)
-866G/G -866G/A -866A/A
(n = 34) (n = 34) (n = 12)
Saturated fatty acids
C14:0 0.37 (0.14) 0.37 (0.12) 0.32 (0.08)
C16:0 28.22 (1.86) 27.88 (2.29) 27.20 (2.38)
C18:0 16.13 (1.77) 17.24 (1.76) 16.72 (2.14)
Total 48.24 (3.34) 49.07 (1.69) 48.18 (2.17)
Trans fatty acids
C16:1n-7 0.12 (0.03) 0.13 (0.03) 0.14 (0.30)
C18:1n-9/7 0.19 (0.11) 0.19 (0.13) 0.17 (0.17)
Total 0.40 (0.12) 0.38 (0.16) 0.38 (0.24)
Monounsaturated fatty acids
C16:1n-7 0.49 (0.19) 0.47 (0.15) 0.44 (0.11)
C18:1n-7 1.17 (0.26) 1.22 (0.24) 1.21 (0.11)
C18:1n-9 7.23 (1.65) 7.08 (1.07) 6.76 (1.55)
12.19 (2.21) 12.51 (1.62) 11.75 (1.71)
C18:2n-6 18.50 (3.47) 18.26 (2.62) 19.10 (2.89)
C18:3n-6 0.07 (0.05) 0.06 (0.04) 0.07 (0.04)
C20:2n-6 0.51 (0.17)a 0.50 (0.10)b 0.41 (0.11)ab
C20:3n-6 3.53 (0.84) 3.56 (1.01) a 3.01 (0.42) a
C20:4n-6 11.34 (2.54) 10.79 (2.74) 11.40 (1.49)
C22:4n-6 0.56 (0.15) 0.54 (0.09) 0.55 (0.17)
C22:5n-6 0.45 (0.15) 0.46 (0.18) 0.49 (0.19)
Σ n-6 LCPUFAc 16.44 (2.60) 16.04 (2.88) 16.50 (2.77)
34.98 (4.17) 34.55 (2.46) 35.53 (2.30)
C18:3n3 0.07 (0.07) 0.06 (0.03) 0.07 (0.07)
C20:3n3 0.03 (0.02) 0.03 (0.01) 0.02 (0.02)
C20:5n-3 0.24 (0.27) 0.23 (0.11) 0.24 (0.08)
C22:5n-3 0.42 (0.27) 0.40 (0.10) 0.39 (0.14)
C22:6n-3 2.56 (0.77) 2.53 (0.93) 2.67 (0.80)
Σ n-3 LCPUFAd 3.37 (1.02) 2.97 (0.95) 3.42 (1.20)
Σ n-3 PUFA  3.46 (1.03) 3.03 (1.00) 3.49 (1.24)
Σ n-6 PUFA
N-3 Polyunsaturated fatty acids
UCP2 genotype:
Total
N-6 Polyunsaturated fatty acids
Data are percentage of weight per weight expressed as median (interqartile
ranges); a,  b p<0.05 between groups. cTotal N-6 long-chain polyunsaturated
fatty acids (LCPUFA) denotes (C20:2n-6 + C20:4n-6 + C22:4n-6 + C22:5n-6). dTotal
N-3 LCPUFA denotes (C20:5n-3 + C22:5n-3 + C22:6n-3).
31
Table 7. Fatty acid composition of plasma sterol esters in 80 obese children
stratified according to genotype in the promoter of the uncoupling protein 2
(UCP2)
-866G/G -866G/A -866A/A
(n = 34) (n = 34) (n = 12)
Saturated fatty acids
C14:0 0.67 (0.28) 0.71 (0.25) 0.80 (0.44)
C16:0 10.85 (1.60) 11.00 (1.19) 11.32 (1.46)
C18:0 1.19 (0.30) 1.28 (0.43) 1.37 (0.22)
Total 13.33 (1.63) 13.55 (1.79) 14.42 (1.88)
Trans fatty acids
C16:1n-7 0.53 (0.10) 0.54 (0.19) 0.59 (0.38)
C18:1n-9/7 0.05 (0.06) 0.08 (0.09) 0.06 (0.03)
Total 0.66 (0.22) 0.66 (0.24) 0.71 (0.44)
Monounsaturated fatty acids
C16:1n-7 2.90 (1.53) 2.98 (1.12) 3.00 (1.57)
C18:1n-7 1.08 (0.31) 1.12 (0.20) 1.07 (0.13)
C18:1n-9 16.58 (2.63) 15.69 (4.03) 13.99 (1.88)
20.68 (3.84) 20.31 (3.84) 18.40 (3.39)
C18:2n-6 53.75 (5.93) 52.83 (6.38) 53.85 (4.73)
C18:3n-6 0.87 (0.51) 0.81 (0.38) 0.86 (0.44)
C20:2n-6 0.12 (0.05) 0.14 (0.05) 0.11 (0.02)
C20:3n-6 0.94 (0.25) a 0.92 (0.23) b 0.73 (0.22) ab
C20:4n-6 8.28 (3.12) 8.14 (2.90) 7.78 (1.38)
C22:4n-6 0.06 (0.07) 0.04 (0.04) 0.05 (0.12)
C22:5n-6 0.05 (0.05) 0.05 (0.03) 0.04 (0.04)
Σ n-6 LCPUFAc 9.62 (2.88) 9.34 (2.99) 8.87 (1.83)
63.90 (4.49) 64.18 (6.30) 64.90 (3.72)
C18:3n3 0.28 (0.11) 0.25 (0.10) 0.27 (0.17)
C20:3n3 0.90 (0.02) 0.92 (0.23) 0.73 (0.22)
C20:5n-3 0.23 (0.15) 0.21 (0.10) 0.24 (0.16)
C22:5n-3 0.01 (0.01) 0.01 (0.02) 0.01 (0.01)
C22:6n-3 0.46 (0.13) 0.45 (0.26) 0.44 (0.11)
Σ n-3 LCPUFAd 0.72 (0.23) 0.70 (0.30) 0.66 (0.28)
Σ n-3 PUFA 1.06 (0.39) 0.96 (0.32) 0.99 (0.36)
Σ n-6 PUFA
N-3 Polyunsaturated fatty acids
UCP2 genotype:
Total
N-6 Polyunsaturated fatty acids
Data are percentage of weight per weight expressed as median (interqartile
ranges); a,  b p<0.05 between groups. cTotal N-6 long-chain polyunsaturated
fatty acids (LCPUFA) denotes (C20:2n-6 + C20:4n-6 + C22:4n-6 + C22:5n-6). dTotal
N-3 LCPUFA denotes (C20:5n-3 + C22:5n-3 + C22:6n-3).
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Table 8. Spearman rank correlation coefficients between arachidonic (C20:4n-6) and
dihomo-γ-linolenic (C20:3n-6) acid values in plasma phospholipids and sterol esters,
on the one hand, and plasma insulin concentrations measured during standard oral
glucose tolerance test, on the other hand, in 80 obese childrenstratified according to
the −866 G/A polymorphism in the promoter of the uncoupling protein 2 (UCP2)
-866G/G -866A/G -866A/A -866G/G -866A/G -866A/A
Phospholopids
Insulin 0' 0.19   0.39   0.52  0.17   0.06  -0.12
Insulin 30' 0.43   0.07   0.04 -0.06   0.28   0.07
Insulin 60' 0.53*   0.47   0.32  0.17   0.40  -0.11
Insulin 90' 0.39   0.40  -0.1 -0.08   0.28   0.18
Insulin 120' 0.44   0.23  -0.12  0.09   0.15   0.1
Insulin 180' 0.15   0.1  -0.07  0.16   0.01  -0.07
Sterol esters
Insulin 0' -0.06 0.39   0.2  0.01  -0.06  -0.80*
Insulin 30'  0.31 0.03   0.32 -0.27   0.37  -0.75*
Insulin 60'  0.51* 0.48*   0.42 -0.08   0.43  -0.75*
Insulin 90'  0.22 0.26   0.28 -0.33   0.17  -0.68
Insulin 120'  0.34 0.29   0.15 -0.07   0.19  -0.44
Insulin 180'  0.09 0.12  -0.35 -0.03   0.07  -0.59
C20:3n-6 C20:4n-6
 UCP2 genotype:
*p<0.008; value calculated by using Bonferroni correction.
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Figure 5. Linear correlation between insulin area under the curve during oral glucose
tolerance test and the values of arachidonic acid in sterol ester lipids in 80 obese
children stratified according to the UCP2 -866 G/A genotype.
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Discussion
In the present study we observed significant differences in the values of important n-
6 LCPUFAs according to -866G/A genotypes of the human uncoupling protein 2
gene in obese children. Furthermore, by correlating the fatty acid levels with the
insulin response and the values calculated for insulin area under the curve during
OGTT we observed considerable differences in relations to -866 polymorphism of
the UCP2.
These differences cannot be explained by different degree of obesity or age.
The negative correlation between 20:4n-6 values and insulin concentrations in the -
866 A/A genotype group might be of special interest, because this group showed
significant reduction in the values of the intermediate precursors of 20:4n-6
synthesis, 20:2n-6 and 20:3n-6. The A allele variant of the -866 G/A polymorphism
is reportedly related to enhanced risk to develop diabetes mellitus (31;32). One of the
potential mechanisms of the relation of altered availability of 20:4n-6 to insulin
sensitivity might be the role of 20:4n-6 as a precursor of various eicosanoids.
Data obtained in this observational study can not answer the question whether
altered availability of C20:4n-6 leads to changes of GIIS, or vice verse. While
decreased UCP2 message might result in diminished energy expenditure and
development of obesity, this very same mechanism would increase insulin secretion
and thus, protect against type 2 diabetes mellitus (109). The association between the
availability of n-6 polyunsaturated fatty acids and GIIS may open further opportunity
to the dietary amelioration of metabolic consequences of obesity. The data obtained
in the present study may provide some general messages for research on fatty acids
in obesity as well. Controversial results seen in previous investigations on LCPUFAs
in apparently similar groups of obese subjects may, at least in part, originate from the
different genetic background including UCP2 polymorphism (38;39).
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3. Systematic review of fatty acid composition of human milk from
mothers of preterm compared to full-term infants
Context
Fatty acid composition of human milk serves as guidance for the composition of
infant formulae. The aim of the study was to systematically review data on the fatty
acid composition of human milk of mothers of preterm compared to full-term infants.
Methods
We performed an electronic literature search in English (Medline
(www.pubmed.com)  and  Medscape  (www.medscape.com))  and  German
(SpringerLink (www.springerlink.com)) databases from their start dates to
November 2005 onwards. The searching expressions were as follows: human milk or
breast milk, combined with essential fatty acid or long-chain polyunsaturated fatty
acid or arachidonic acid or docosahexanoic acid. We also checked the list of
references in the publications identified. We attempted to reveal unpublished
evidence by consulting abstract books of relevant scientific meetings and by
contacting experts working in this field.
Fatty  acid  composition  of  preterm  or  full-term  human  milk  was  reported  in
several  studies,  whereas  data  obtained  in  direct  comparison  of  the  fatty  acid
composition of preterm and full-term human milk within the same study were
published only in five reports. Each of these studies were longitudinal studies and
investigated human milk from apparently healthy mothers who had delivered preterm
or full-term infants. Both pregnancies and deliveries were normal in all these studies.
The gestational ages of preterm infants were between 25 and 36 weeks, whereas
those of full-term infants were over 37 weeks. There was no history of any disease of
the offspring. All the women in the study of Genzel-Borovicezény et al., Luukkainen
et al. and Kovács et al. were apparently on omnivorous diet. No information was
given about the dietary background of mothers in the study of Bitman et al. and
Rueda et al.
There were some methodological differences in the studies reviewed here. The
sample collections were at different time points of lactation (for details see results).
Storage  temperature  of  the  milk  samples  was  either  -20°C  or  -70°C  or  -80°C.  For
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fatty acid analysis, lipids were extracted either with chloroform-methanol or using a
mixture of benzene-methanol-acetylchloride. Fatty acid methylesters were
determined by capillary gas liquid chromatography in all studies except the classical
study of Bitman et al (54), who used packed column gas liquid chromatography
being the predominant method at the time. Results of the fatty acid composition were
expressed as weight percentages of all fatty acids and were presented as means and
SD (57), means and SE (54), median and IQR (56;58) or means and 95% confidence
intervals (55). For a better comparability, we calculated all data into the form of
means and SD from the published data or the original data bases of the two studies
where medians and interquartile ranges were published (56;58). For arachidonic acid
(AA) and docosahexanoic acid (DHA) values, i.e. the principal LCPUFAs of human
milk we also calculated the difference of means between preterm and full-term milk
and the 95% confidence intervals (CIs) of the difference of means by using the
following formulae:
PSD = )2/()1()1[( 21222111 -+-+- NNssNssN xx
SED = PSD x )]/1()/1[( 21 NN +
95% CI = (X1-X2) ± t* x SED
(Abbrevations: PSD = Pooled SD, N1 = number of subjects in group one (in our
study: preterm), s1 =  standard  deviation  of  group  one,  N2 =  number  of  subjects  in
group two (in our study: full-term), s2 = standard deviation of group two; SED =
Standard Error of the Difference, X1 = mean of group one, X2 = mean of group two,
t* = value of t-distribution at the given confidence level with degree of freedom = N1
+ N2 -2.)
Results
Fatty acid compositions of preterm and full-term human milk investigated in 18
comparisons published in 5 studies are shown in Tables 9, 10 and 11.
Preterm breast milk showed higher contents of the saturated fatty acids myristic
acid (C14:0) at two different time points in the study of Kovács et al (58) and in the
study of Genzel-Boroviczény et al (56), palmitic acid (C16:0) values at one time
point  in  the  study  of  Kovács  et  al  (58)  and  stearic  acid  (C18:0)  values  at  one  time
point in the study of Luukkainen et al (55) (Table 9). The cis monounsaturated fatty
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acid oleic acid (C18:1n-9) was higher in preterm milk at two different time points in
the study of Kovács et al (58) and at three different times in the study of Rueda et al
(57) (Table 9). Values of the principal n-6 polyunsaturated fatty acids, linoleic acid
(C18:2n-6, LA), GLA and AA values were reported in all studies, whereas DHGLA
values were reported only in four studies. Data on the principal n-3 polyunsaturated
fatty acids, docosapentaenoic acid (C22:5n-3) and docosahexaenoic acid (C22:6n-3,
DHA) were reported in all studies, whereas eicosapentaenoic acid (C20:5n-3, EPA)
values were reported only in four and alpha-linolenic acid (C18:3n-3, ALA) values in
3 studies.
Values of LA, ALA and EPA did not differ between preterm and full-term
human milk in any of the five studies. In contrast, GLA values were significantly
higher in colostrum of mothers giving birth to preterm infants than in those
delivering at term in the study of Kovács et al (58). Values of the principal n-3
LCPUFA DHA were significantly higher in preterm breast milk at 1, 4, 7, 14 and 21
days,  and  of  the  n-6  LCPUFA AA at  all  time points  except  day  14  in  the  study  of
Kovács et al (58), whereas both fatty acids were found at higher levels only at days
28-35 by Luukkainen et al (55) (Tables 10 and 11). Values of the major intermediary
metabolite of the synthesis of AA, DHGLA were found to be significantly higher in
milk samples obtained from mothers of preterm than in those collected from mothers
of full-term infants in the study of Kovács et al (58), and values of C22:5n-3
(intermediary metabolite of the synthesis of DHA) were significantly higher in
preterm breast milk in the study of Kovács et al (58) at 7 and 21 days, and in the
study of Luukkainen et al (55) at 12 and 26 weeks (Table 10 and 11).
The differences of the means and the 95% confidence intervals (CIs) of the
difference for DHA and AA values measured in milk samples obtained from mothers
of preterm and full-term infants in the five studies are shown in Figure 6 and Figure
7, respectively. The difference of mean DHA values (preterm vs term) were
significantly different from zero in 3 studies (55;56;58), covering 3 different time
points. In the study of Kovács et al (58) AA value difference were positive at 3
different  time  points  of  lactation;  whereas  the  data  of  Rueda  et  al  (57)  showed
negative 95% CIs for AA values at 2 different time points of lactation.
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Figure 6. The differences of the means and the 95% confidence intervals (CIs) of the
difference for arachidonic acid values measured in milk samples obtained from
mothers of preterm and full-term infants in five studies. Each horizontal line
represents one statistical comparison. The middle symbol on the horizontal line
depicts mean value, whereas the lateral symbols show 95% CIs. Symbols: ®: Bitman
et al (Bitman): preterm (upper line) and very preterm (lower line) at day 42 ¢:
Luukainen et al (Luukainen): at days: 1-7, 8-14, 15-21, 22-27, 28-35 (top down) :
Genzel-Boroviczeny et al (Genzel-Boroviczeny): at days: 5, 10, 20 and 30 (top
down) ®: Rueda et al (16) at days: 1-5, 6-15 and 16-35 (top down) ¢: Kovács et al
(Kovacs) at days: 1, 4, 7, 14 and 21 (top down)
Figure 7. The differences of the means and the 95% confidence intervals of the
difference for docosahexaenoic acid values measured in milk samples obtained from
mothers of preterm and full-term infants in five studies. For further details of legend
see Figure 6.
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Table 9. Major saturated and cis monounsaturated fatty acids in preterm and full-term human milk
Data are in weight percent presented as means (SD). * p< 0.05, ** p< 0.001, VPT denotes very preterm and PT denotes preterm.
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Table 10. Major n-3 polyunsaturated fatty acids in preterm and full-term human milk
n.d. denotes not determined. For symbols, abbrevations and number of samples analysed see Table 1.
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Table 11. Major n-6 polyunsaturated fatty acids in preterm and full-term human milk
n.d. denotes not determined. For other symbols, abbrevations and number of samples analysed see Table 1.
42
Discussion
In the present review, we identified 3 independent studies (55;57;58) covering 3
different  time points  of  lactation  were  the  95% CIs  of  the  significant  difference  of
mean DHA values (preterm minus full-term) were entirely in the positive range, i.e.
the percentage contribution of DHA is higher in preterm than full-term milk. In
contrast, data for AA were rather controversial: in the study of Kovács et al (58) the
95% CIs for AA values were entirely in the positive range at 3 different time points
of  lactation,  whereas  in  the  study  of  Rueda  et  al  (57)  the  95%  CIs  for  AA  values
were entirely in the negative range at 2 different time points of lactation, i.e. both
significantly higher and lower AA levels were reported in preterm compared to full-
term human milk.
The LCPUFA content of human milk is closely related to maternal LCPUFA
body stores (110-112). Mothers of premature infants transfer less LCPUFAs to the
fetus during a shorter pregnancy, and also the volume of human milk consumed by
their infants tends to be much smaller particularly during the first weeks after birth
(56), which would lead to higher maternal LCPUFA stores and thus may explain
higher LCPUFA values in preterm than in full-term human milk (58). Due to the
shorter period and lesser extent of intrauterine LCPUFA accumulation, preterm
infants should have higher postnatal LCPUFA requirements than full-term infants. It
is tempting to speculate whether there may be other adaptive or regulative
mechanism to indicate higher LCPUFA contents in preterm milk in response to
higher physiological needs of preterm infants, but the occurrence of a significant
survival rate of small preterm infants is a very new phenomenon relative to the time
scale of human evolution and hence it appears unlikely that such mechanisms
specific to preterm birth would have developed.
Nonetheless,  higher  DHA  values  in  preterm  than  in  full-term  human  milk
indicate a likely benefit of utilising own mother’s milk for feeding preterm infants.
Moreover, these data should lead to a reconsideration of the DHA levels in formulae
for preterm infants, which currently tend to mimic DHA levels of full-term human
milk and thus tend to differ from the fatty acid composition of human milk of
mothers giving birth to preterm infants.
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4. Prevalence of metabolic syndrome in European obese children
Context
The rapid rising prevalence of childhood obesity is related to increased risk of
obesity-related diseases during adulthood. The aim of the present study was to
review the data concerning the prevalence of metabolic syndrome (MS) in European
children and adolescents (Part a) and to determine and compare the prevalence of MS
among overweight and obese children, and adolescents in five European countries
using four MS definitions (Part b).
a.) Review of the data concerning the prevalence of metabolic syndrome in
European children and adolescents
Methods
We performed an electronic literature search in (Medline (www.pubmed.com) and
Medscape (www.medscape.com)) databases from their  start  dates to February 2008
onwards. The searching expressions were as follows: metabolic syndrome,
cardiovascular syndrome, children, adolescents. We also checked the list of
references in the publications identified.
Results
In Table 12, we summarize the studies on the prevalence of MS in children and
adolescents performed in Europe combined with our own, recent results. Only few
studies investigated the prevalence of MS in European countries as a primary goal.
The studies were performed in Middle and South part of Europe (Spain, Italy,
France,  Germany,  and  Hungary),  and  only  one  in  the  North  (UK).  Except  of  two
studies (113;114), the investigations were performed only on overweight and obese
children and adolescents with a small number of subjects included. The used
definitions were either based on the adult definitions from WHO or NCEP, modified
with children specific cut-offs, or previously published definitions used to define MS
in children. A big variance in the prevalence of MS (8.5% to 50%) can be observed
among the studies; however, the results are not comparable since the used definitions
were different.
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A  low  degree  of  overlap  among  the  different  MS  definitions  is  pointed  out  in  two
studies (Reinehr et al (114), and for our results see part b), where more definitions
were used.
Table 12. The prevalence of metabolic syndrome in childhood and adolescence in
studies performed in Europe
Study Study population Definition Prevalence (%)
Csábi et al.
(Hungary; 2000)
8-18-y old, 180 obese and 239
control
WHO*
obese: 8.9
Viner et al.
(UK; 2005)
2-18-y old, 103 obese WHO* 33
Invitti et al.
(Italy; 2006)
6-16-y old, 588 obese WHO* 23,3
Druet et al.
(France 2006)
308 obese and overweight NCEP* 15,9
López-Capapé et al.
(Spain; 2006)
4-18-y old, 429 obese and
overweight
Cook
18,0
Bueno et al.
(Spain; 2006)
Age: 10.8 (2.3) mean (SD),
103 obese
Cook
29,9
de Ferranti
50
Sartorio et al.
(Italy 2007)
8-18-y old, 439 obese Weiss
n.d.
EPS: 29.9 ♂, 19.2 ♀
LPS: 52.1 ♂, 28.9 ♀
Italian Society for Pediatrics n.d.
Reiner (23)
(Germany 2007)
9.5-13.3-y old, n=1205
overweight and obese; 84
normal weight
Cook
21
De Ferranti 39
Viner 18
Weiss 29
EGIR 8
WHO 6
NCEP 13
IDF 14
4.5-18.2-y old, 1241 obese and
overweight
De Ferranti
35,7
WHO* 31,4
NCEP* 20,3
IDF for children 16,4
Cook
Our results (part b)
(Hungary, France, Italy,
Greece, Poland)
WHO, World Health Organisation; NCEP, National Cholesterol Education Program;
EGIR, European Group for the Study of Insulin Resistance; IDF, International
Diabetes Federation. * modified with children specific cut off values, EPS: early-mid
pubertal stage, LPS: late pubertal stage, n.d.: data not shown.
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b.) To determine and compare the prevalence of MS among overweight and
obese children and adolescents in five European countries using four MS
definitions
Materials and Methods
The investigations were carried out in 1241 overweight children and adolescents
from five European countries (Hungary: n=449, France: n=283, Italy: n=274,
Greece: n=145 and Poland: n=90), referred for clinical evaluation because of their
overweight  to  the  Department  of  Pediatrics,  University  of  Pécs,  Hungary;  Saint
Vincent de Paul Hospital, AP-HP, Paris and CTP, Margency, France; Department of
Pediatrics, University of Rome „Sapienza”, Italy; Department of Endocrinology, „P.
& A. Kyriakou” Children’s Hospital, Athens, Greece; Department of Pediatric
Endocrinology & Diabetes, Medical University of Silesia, Katowice, Poland.
None of the subjects had chronic disease, secondary obesity, received drug treatment
or were on restricted diet. We considered children as obese if their body mass index
exceeded the value of Cole et al. (6) corresponding to 25 at the age of 18 years. The
clinical characteristics of patients in the five different countries are shown in Table
13. Anthropometric measurements were performed according to harmonized
methods as described by Lohman et al. (115). Body mass index was computed as
weight (kilogram) divided by squared height (m2). Blood glucose, serum insulin and
lipid levels were determined from blood samples taken after an overnight fast.
Plasma glucose concentrations were determined by the glucose oxidase or
hexokinase method. Triglyceride and cholesterol concentrations were measured with
an enzymatic kit and HDL-C using a corresponding non precipitating method.
Plasma insulin concentrations were measured with commercially available
radioimmunoassay or chemiluminescence method. A comparison test was performed
between the two methods. The correlation between the results was calculated: y =
0.99x, with r = 0.95. Homeostasis model assessment for insulin resistance (HOMA-
IR) was calculated with the following formula: (fasting insulin x fasting
glucose)/22.5. Blood pressure (BP) was measured after 5 min rest, while sitting to
the nearest 2 mmHg, using a standard mercury-gravity manometer with proper cuff
size in each subject three times. The average of three measurements obtained on
different days was used in the analysis (116).
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Table 13. Clinical and biological characteristics of obese children according to nationality. Data are expressed as mean (SD).
Whole group Polish Greek Italian French Hungarian
(n = 1241) (n = 90) (n = 145) (n = 274) (n = 283) (n = 449)
Boys/Girls 560/681 39/51 74/71 135/139 91/192 221/228 < 0.001
Age (years) 12.9 (2.5) 12.9 (3.3) 11.3 (2.5) 12.1 (1.6) 14.5 (1.6) 12.9 (2.7) < 0.001*
Weight (kg) 80.53 (24.1) 78.7 (24.5) 70.4 (20.9) 63.9 (13.9) 102.4 (19.9) 80.5 (21.7) < 0.001**
Height (cm) 158.2 (12.8) 158.4 (16.0) 151.3 (14.6) 153.6 (9.4) 164.5 (8.4) 159.4 (13.5) < 0.001**
Waist cc (cm) 91.9 (12.9) 93.9 (12.7) 95.3 (13.1) 83.9 (10.6) 102.1 (11.3) 89.2 (10.4) < 0.001**
BMI (kg/m2) 31.5 (6.1) 30.8 (4.9) 30.1 (4.9) 26.8 (3.6) 37.7 (5.9) 31.1 (4.8) < 0.001**
Triglyceride (mmol/l) 1.2 (0.9) 1.2 (0.6) 1.3 (0.3) 1.1 (0.6) 1.0 (0.5) 1.5 (1.22) < 0.001***
HDL-cholesterol (mmol/l) 1.2 (0.3) 1.4 (0.3) 1.3 (0.3) 1.3 (0.3) 1.2 (0.4) 1.18 (0.30) < 0.001***
Glucose (mmol/l) 4.8 (0.6) 4.9 (0.4) 5.2 (0.5) 4.9 (0.5) 4.5 (0.5) 4.8 (0.8) < 0.001***
Insulin (μU/ml) 23.0 (15.7) 14.3 (7.9) 19.4 (13.9) 20.7 (11.8) 18.1 (12.8) 30.2 (17.9) < 0.001***
SBP (mmHg) 120.6 (13.4) 111.3 (13.4) 121.9 (12.5) 115.9 (11.3) 119.7 (14.8) 125.4 (11.9) < 0.001***
DBP (mmHg) 70.9 (10.5) 72.4 (9.5) 62.9 (10.9) 76.9 (9.6) 67.5 (10.1) 71.8 (8.8) < 0.001***
p
BMI, body mass index; HDL-cholesterol, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic
blood pressure. p values: comparison among countries, * adjusted for nationality and gender, ** adjusted for nationality, age and
gender; *** adjusted for nationality, age, gender and BMI.
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Statistical analysis
Results were evaluated with SPSS for Windows, Release 11.5 (SPSS Inc., Chicago,
IL,  USA).  All  data  are  presented  as  mean  (SD).  The  clinical  features  of  obese
children stratified according to nationality were compared with analysis of variance
followed by post-hoc LSD test. Because the age and BMI differed significantly
between groups we adjusted the biochemical parameters and blood pressures for
nationality, age, gender and BMI, and compared the adjusted parameters with LSD
test. Results were regarded as statistically significant at p<0.05.
Definition of Metabolic Syndrome
Children were classified as displaying MS according to four different definitions.
Two definitions  were  child-specific  (Ferranti  et  al.  (79),  and  International  Diabetes
Federation (78)) while the other two (World Health Organisation (73) and National
Cholesterol Education Program Adult Treatment Panel III (75)) adult-specific.
In the case of WHO criteria we omitted microalbuminuria because measurements
were available only for a subset of children and we replaced waist-hip ratio with
waist circumference since sex and age specific reference values were not available
for waist-hip ratio. The highest quartile for insulin was 15 μU/ml (the highest 25%
value of 100 healthy adolescents). The WHO definition was applied only in 1201
children because of missing plasma insulin values in 40 children. Age and gender
specific reference values were used in all definitions for the diagnosis of high blood
pressure and increased waist circumference (116;117).
Results
Table 13 shows the clinical features of obese children according to nationality after
adjustment for nationality, age gender and BMI. Triglyceride and insulin levels and
the systolic blood pressure were highest in Hungarian, while fasting plasma glucose
in Greek, and diastolic blood pressure in Italian children were the highest as
compared to children from other countries.
The prevalence of MS in the investigated cohort was 35.7%, 31.4%, 20.3%, and
16.4% according to the Ferranti, WHO, NCEP and IDF definitions, respectively
(Figure 8).
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Figure 8. The prevalence of metabolic syndrome in the investigated cohort. WHO,
World Health Organisation; NCEP, National Cholesterol Education Program; EGIR,
European  Group  for  the  Study  of  Insulin  Resistance;  IDF,  International  Diabetes
Federation
The prevalence of MS was not different between genders. The prevalence of risk
factors according to the different definitions is shown in Table 14.
The prevalence of increased waist circumference was high (71.4%). Due to
different cut off values the occurrence of low HDL levels varied according to
definitions. We found, as expected, the highest prevalence of elevated triglyceride
levels according to Ferranti et al. and of elevated fasting plasma glucose according to
the  definition  of  IDF  because  of  the  lower  cut  off  values  applied  for  these  risk
factors.
The clustering of risk factors in the investigated cohort is shown in Table 14. Only
6.3-8.8% of obese adolescents were free from any risk factor, and the clustering of
three or more risk factors was very high (20.3-35.7%) (depending on the type of
definition).
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Table 14. Prevalence  and  clustering  of  risk  factors  according  to  the  criteria  of
Ferranti et al., WHO, NCEP and IDF
Ferranti et al WHO NCEP IDF
Increased waist circumference 71.4% 71.4% 71.4% 71.4%
High fasting plasma glucose 2.3% 2.3% 2.3% 8.6%
High fasting plasma insulin* 64.7%
High triglyceride 42.8% 15.1% 15.1% 15.1%
Low HDL-cholesterol 48.5% 13.0% 46.4% 27.6%
High blood pressure 38.1% 38.1% 38.1% 38.1%
No risk factor 6.3 % 6.5 % 8.8 % 11.3 %
1 risk factor 25.1 % 26.2 % 32.2 % 37.9 %
2 risk factors 32.9 % 34.7 % 38.7 % 33.5 %
3 or more risk factors 35.7 % 32.6 % 20.4 % 17.3 %
NCEP, National Cholesterol Education Program; WHO, World Health Organisation;
IDF, International Diabetes Federation, HDL-cholesterol: high-density lipoprotein
cholesterol * in n = 1201 investigated subjects.
We calculated the number of children who had MS by all four, three, two, one and
none  of  the  definitions  (Figure  9). It is worth mentioning that 12.2% (n=147) of
children had MS and 55.8% (n=670) were free of MS according to all four
definitions.
Figure 9. Frequency of metabolic syndrome if one, two, three or four definitions are
applied.
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The prevalence of MS was significantly influenced by the degree of obesity,
characterised by BMI or waist circumference (Table 15), but not by age.
Table 15. Effect  of  age,  BMI  and  waist  cc  on  the
prevalence  of  MS  according  to  all  four  definition  (n  =
1201).
<Q1 <Q3 >=Q3
age 49 (15.8%) 133 (14.8%) 43 (14.1%)
BMI 18 (5.9%)a 110 (12.2%)b 66 (22.2%)
waist cc 22 (7.9%)a 112 (12.1%)b 64 (23.4%)
Q1: quartile1, Q3: quartile3; a, b p < 0.001 compared to >Q3
Discussion
The results showed the high prevalence of MS ranging from 16.4% to 35.7% in
overweight and obese children referred to outpatient clinics. The prevalence of MS
was highly dependent on the definition used. The accordance among the definitions
was small, only 12.2% of investigated subjects had MS according to all 4 definitions.
The observed prevalence of MS in our study is in agreement with earlier reports
investigating the prevalence of childhood MS (79;113;114;118-123). However, the
results of these studies are not comparable since the definitions they used for the
childhood MS were different.
The disparity between different definitions is related to the different cut off
values and pooling strategies of MS criteria. The highest prevalence of MS (35.7%)
was found according to the definition of Ferranti et al. (79) using the lowest cut off
values for triglyceride and the highest for HDL-cholesterol levels. The WHO (73)
was the only definition including fasting insulin as a criterion. The high prevalence
of hyperinsulinemia (64.7%) explains why WHO definition identified more children
with MS than the IDF and NCEP.
Our results demonstrated that only 6.3-11.3% of overweight and obese children
were free from any risk factors, and 17.3-35.7% had already more than 3 risk factors,
underlining the fact that clustering of risk factors starts in childhood. The prevalence
of high waist circumference was 71%, showing that the majority of children had
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central obesity and consequent insulin resistance (64.7% hyperinsulinemic). The
prevalence of high blood pressure was also frequent – mounting to 38% in the
cohort.
There was a significant difference in the biological characteristics of children
according to nationality, even if we adjusted the values for nationality, age, gender
and BMI. These differences can be attributed to different referral rules. Different
dietary and lifestyle habits can also contribute to the difference in the MS prevalence
between the 5 cohorts.
In the present cohort, the prevalence of MS increased with the increasing degree
of obesity (BMI and waist circumference) in accordance with previous studies (69).
There are certain limitations of the present study. Our cohort is not a population-
based sample and might not even reflect the European obese children’s population.
However, it represents a large proportion of European obese children referred to
obesity  centres.  Further  weakness  of  our  study  is  that  the  different  biochemical
parameters were not determined in one laboratory, however the methodology was the
same in all  five centres.  Though the comparability of the two methods used for the
determination  of  insulin  was  high,  the  variability  between  kits  still  has  to  be
considered. Finally, the effect of pubertal development on prevalence of MS could
not be analysed since data on pubertal stage were not available.
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New findings of the study
1. The results of the present study on the common single nucleotide polymorphism at
CD36 locus showed that rs3211908 was consistently associated with obesity and
BF% in adolescents. The rs3211867, rs3211883 and rs1527483 were also related to
obesity  risk  and  BF%  but  the  associations  were  weaker.  The  later  SNPs  are  in
linkage disequilibrium with rs3211908 (0.43< r2 <0.64) suggesting that these
associations reflect a single signal. In contrast, rs1527479, rs3211816 and rs3211931
were not linked to excess fat depot phenotype. Further analyses identified a
haplotype with the minor allele of rs3211908 (frequency 4%) that is linked to
increased risk of obesity in the case-control study and excess adiposity in the cross-
sectional study suggesting that rs3211908 is responsible for the excess risk among
other SNPs. Collectively, these findings suggest that CD36 gene variability may
contribute to the risk of body fat accumulation in adolescents.
2. In the present study we observed significant differences in the values of important
n-6 LCPUFAs according to -866G/A genotypes of the human uncoupling protein 2
gene in obese children. Furthermore, by correlating the fatty acid levels with the
insulin response and the values calculated for insulin area under the curve during
OGTT we observed considerable differences in relations to -866 polymorphism of
the UCP2.
3. In the present review, we identified 3 independent studies covering 3 different
time points of lactation were the 95% CIs of the significant difference of mean DHA
values (preterm minus full-term) were entirely in the positive range, i.e. the
percentage contribution of DHA is higher in preterm than full-term milk. This
finding supports the concept that fomuale for preterm infants should be
supplemeneted with DHA. Moreover, the significantly higher contribution of DHA
to the fatty acid composition of preterm than to that of full-term human milk
questions the present practice to use the fatty acid composition of full-term human
milk as model for the DHA content of formulae for preterm infants.
4. The results showed the high prevalence of MS ranging from 16.4% to 35.7% in
overweight and obese children referred to outpatient clinics. The prevalence of MS
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was highly dependent on the definition used. The accordance among the definitions
was small, only 12.2% of investigated subjects had MS according to all 4 definitions.
Our results demonstrated that only 6.3-11.3% of overweight and obese children were
free from any risk factors, and 17.3-35.7% had already more than 3 risk factors,
underlining the fact that clustering of risk factors starts in childhood.
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Clinical consequencies of the study
1. Because the CD36 receptor is theoretically considered to play an important role in
determining the susceptibility to the development of obesity, genetic characterisation
of subgroups with actually increased risk of obesity may contribute to our better
understanding of the link between receptor and clinical outcome.
2. The association between the availability of n-6 polyunsaturated fatty acids and
glucose induced insulin secretion may open further opportunity to the dietary
amelioration of metabolic consequences of obesity. The data obtained in the present
study may provide some general messages for research on fatty acids in obesity as
well. Controversial results seen in previous investigations on LCPUFAs in
apparently similar groups of obese subjects may, at least in part, originate from the
different genetic background including UCP2 polymorphism.
3. Higher DHA values in preterm than in full-term human milk indicate a likely
benefit of utilising own mother’s milk for feeding preterm infants. Moreover, these
data should lead to a reconsideration of the DHA levels in formulae for preterm
infants, which currently tend to mimic DHA levels of full-term human milk and thus
tend to differ from the fatty acid composition of human milk of mothers giving birth
to preterm infants.
4. The prevalence of metabolic syndrome is high in European overweight and obese
children referred to obesity centres, whatever definition is used. Overweight and
obese children, especially those with high waist circumference, have to be screened
for MS. An unified childhood-specific definition of MS is needed in order to gain
comparable study results and to avoid the possibility of different diagnosis of the
same individual depending on the country he/she lives in and on the criteria used.
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